ACRIA Current Studies
People who have not taken anti-HIV drugs (or for less than 2 weeks) will take one of several doses of GW873140 (a CCR5 antagonist) and take Combivir, for 96 weeks. Participants must be 18 or older and have a viral load of at least 10,000 and CD4 count greater than 100. Study participants will be reimbursed $25 for each regular visit and $200 for one 12-hour PK visit.
People who have taken anti-HIV drugs from three of the four classes of drugs will take either UK-427 (an experimental HIV CCR5 attachment inhibitor) with an optimized regimen of anti-HIV drugs, or take a placebo (dummy pill) with the optimized regimen, for 11 months. Participants must be 16 or older and have a viral load of at least 5,000.
People who have high cholesterol levels and a viral load below 50 while taking Kaletra will either switch to Reyataz or continue taking Kaletra. The study will last 12 months. Study participants will be reimbursed $25 for each visit.
People whose viral load has risen to over 1,000 while taking an NNRTI as part of their first HAART regimen will switch to either Kaletra, or to Reyataz/Norvir. Everyone will also take Viread and either Videx EC or Zerit XR. The study will last for 22 months. Study participants will be reimbursed $25 for each visit.
People whose viral load has risen to over 1,000 while taking Reyataz will have blood tests for resistance, CD4 and viral load. Study participants will be reimbursed $25.
For the above trials, contact Dr. Douglas Mendez at 212-924-3934 ext. 126 or Dr. Yuriy Akulov at ext. 124.
People in this large study of older adults with HIV will fill out a survey about physical and behavioral health, social networks, quality of life and spirituality. Participants must be 50 or older and be able to read and complete a questionnaire. Study participants will be reimbursed $25 for one visit.
For the ROAH Program, contact Andrew Shippy at 212-924-3934 ext. 104.
This article was provided by AIDS Community Research Initiative of America. It is a part of the publication ACRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.